EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)

Leandro Jonata de Carvalho Oliveira iD, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo, Daniela Dornelles Rosa, Artur Katz iD, Daniele Assad-Suzuki iD, Daniel Argolo, Solange Moraes Sanches, Laura Testa iD, José Bines iD, Rafael Aliosha Kaliks iD, Debora de Melo Gagliato iD und 18 weitere

JCO Oncology Practice · 2026-11 · 22 (11) · 1953-1962

DOI: 10.1200/op-25-00899 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Oncology Practice, 2026-11. Verfasst von Leandro Jonata de Carvalho Oliveira und 29 weiteren Autor:innen. Beteiligte Einrichtung: Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), São Paulo, Brazil. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oncotype DX (ODX) is a validated gene expression assay that provides prognostic and predictive information to guide adjuvant chemotherapy (ACT) decisions in hormone receptor–positive, HER2-negative (HR+/HER2–) early breast cancer (eBC), including node-negative (N0) and 1-3 node-positive (N1) disease. In Brazil, limited access to gene expression signatures (GES) remains a barrier to individualized treatment decisions. METHODS We conducted a multicenter retrospective study across nine Brazilian private cancer centers to evaluate clinicopathologic predictors of high genomic risk (ODX recurrence score [RS] >25) and to assess the clinical impact of ODX on ACT decision making. RESULTS Between 2005 and 2024, 935 patients were included, with a notably higher representation of young (≤40 years: 10.9%) and premenopausal (40.7%) women than typically reported in randomized clinical trials. Ki-67 >20%, progesterone receptor (PR) expression ≤30%, and histologic grade 3 were independently associated with high RS in both univariable and multivariable analyses (all P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesGene Expression ProfilingHumansFemaleBrazilRetrospective StudiesMiddle AgedReceptors, ProgesteroneAdultReceptors, EstrogenPrognosisAgedBiomarkers, Tumor

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanReceptors, ProgesteroneReceptors, EstrogenBiomarkers, Tumor

Autor:innen und Institutionen

  • Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), São Paulo, Brazil.
  • Instituto de Ensino e Pesquisa Sírio-Libanês, São Paulo, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Huna, São Paulo, Brazil.
  • Serviço de Oncologia, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Centro de Oncologia, Hospital Sírio-Libanês, São Paulo, Brazil.

ORCID-Profile: Leandro Jonata de Carvalho Oliveira, Artur Katz, Daniele Assad-Suzuki, Laura Testa, José Bines, Rafael Aliosha Kaliks, Debora de Melo Gagliato, Romualdo Barroso-Sousa, Andrea Kazumi Shimada, Carlos Henrique Dos Anjos, Rudinei Linck, Larissa Matos Almeida Moura, Renata Colombo Bonadio, Zenaide Silva de Souza, Juliana Rodrigues Beal, Mario Machado Lopes, Júlia Leal Franco Parisi Marlière, Max Senna Mano

Zitieren

APA

Oliveira, L. J. C., Araújo, D. C., de Araújo, J. A. P., Rosa, D. D., Katz, A., Assad-Suzuki, D., Argolo, D., Sanches, S. M., Testa, L., Bines, J., Kaliks, R. A., Gagliato, D. M., Barroso-Sousa, R., Corrêa, T. S., Shimada, A. K., Dos Anjos, C. H., Linck, R., Megid, T. B. C., Batista, D. N., …, & Mano, M. S. (2026). Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520). JCO Oncology Practice, 22(11), 1953-1962. https://doi.org/10.1200/op-25-00899

Vancouver

Oliveira LJC, Araújo DC, de Araújo JAP, Rosa DD, Katz A, Assad-Suzuki D, et al. Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520). JCO Oncology Practice. 2026;22(11):1953-1962. doi:10.1200/op-25-00899

BibTeX
@article{Oliveira2026,
  author = {Oliveira, Leandro Jonata de Carvalho and Araújo, Daniella Castro and de Araújo, Júlio Antonio Pereira and Rosa, Daniela Dornelles and Katz, Artur and Assad-Suzuki, Daniele and Argolo, Daniel and Sanches, Solange Moraes and Testa, Laura and Bines, José and Kaliks, Rafael Aliosha and Gagliato, Debora de Melo and Barroso-Sousa, Romualdo and Corrêa, Tatiana Strava and Shimada, Andrea Kazumi and Dos Anjos, Carlos Henrique and Linck, Rudinei and Megid, Thais Baccili Cury and Batista, Daniel Negrini and Gomes, Daniel Musse and Cesca, Marcelle Goldner and Gaudêncio, Débora and Moura, Larissa Matos Almeida and Bonadio, Renata Colombo and de Souza, Zenaide Silva and Beal, Juliana Rodrigues and Lopes, Mario Machado and Sales, Leticia Telles and Parisi Marlière, Júlia Leal Franco and Mano, Max Senna},
  title = {Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520)},
  journal = {JCO Oncology Practice},
  year = {2026},
  volume = {22},
  number = {11},
  pages = {1953--1962},
  doi = {10.1200/op-25-00899}
}
Kostenlos starten →